Age-Related Macular Degeneration: Advances in Management and Diagnosis
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Age-related macular degeneration (AMD) is the most common cause of irreversible visual impairment in older populations in industrialized nations. AMD is a late-onset deterioration of photoreceptors and retinal pigment epithelium in the central retina caused by various environmental and genetic factors. Great strides in our understanding of AMD pathogenesis have been made in the past several decades, which have translated into revolutionary therapeutic agents in recent years. In this review, we describe the clinical and pathologic features of AMD and present an overview of current diagnosis and treatment strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337 · cited 1×
“0 mg pegaptanib intravitreal injections every six weeks [65].”
Prevalence of age-related maculopathy
Klein, R., Klein, B. E. K., & Linton, K. L. P. (1992) · Ophthalmology · doi:10.1016/s0161-6420(92)31871-8 · Cited by 1,845
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Martin, D. F., Maguire, M. G., Fine, S. L., Ying, G.-S., Jaffe, G. J., Grunwald, J. E., Toth, C., Redford, M., & Ferris, F. L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.03.053 · Cited by 1,715
Schwartz, S. D., Regillo, C. D., Lam, B. L., Eliott, D., Rosenfeld, P. J., Gregori, N. Z., Hubschman, J.-P., Davis, J. L., Heilwell, G., Spirn, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61376-3 · Cited by 1,327 · cited 1×
“photoreceptors [48,49], neuroprotection [1,50–53], and stem cell transplantation [54,55].”
Brown, D. M., Michels, M., Kaiser, P. K., Heier, J. S., Sy, J. P., & Ianchulev, T. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2008.10.018 · Cited by 1,318
Prevalence of age-related maculopathy in Australia
Mitchell, P., Smith, W., Attebo, K., & Wang, J. J. (1995) · Ophthalmology · doi:10.1016/s0161-6420(95)30846-9 · Cited by 1,062
Ageing and degeneration in the macular region: A clinico-pathological study
Sarks, S. H. (1976) · British Journal of Ophthalmology · doi:10.1136/bjo.60.5.324 · Cited by 891
The Prevalence of Age-related Maculopathy in the Rotterdam Study
Vingerling, J. R., Dielemans, I., Hofman, A., Grobbee, D. E., Hijmering, M., Kramer, C. F. L., & de Jong, P. T. V. M. (1995) · Ophthalmology · doi:10.1016/s0161-6420(95)31034-2 · Cited by 815
Racial Differences in the Cause-Specific Prevalence of Blindness in East Baltimore
Sommer, A., Tielsch, J. M., Katz, J., Quigley, H. A., Gottsch, J. D., Javitt, J. C., Martone, J. F., Royall, R. M., Witt, K. A., & Ezrine, S. (1991) · New England Journal of Medicine · doi:10.1056/nejm199111143252004 · Cited by 764 · cited 4×
“For example, at 80 years or older, the prevalence of neovascular AMD in Caucasians was 11.1% for women and 8.3% for men, compared to 1.8% and 0.9%, respectively, in African Americans.”
InfluentialDICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88
Tarallo, V., Hirano, Y., Gelfand, B. D., Dridi, S., Kerur, N., Kim, Y., Cho, W. G., Kaneko, H., Fowler, B. J., Bogdanovich, S., et al. (2012) · Cell · doi:10.1016/j.cell.2012.03.036 · Cited by 592 · cited 1×
“Other promising concepts being explored as therapeutic strategies include methods that target inflammasomes [47], the visual pigment cycle in”
Risk factors for neovascular age-related macular degeneration
(1992) · Archives of Ophthalmology · doi:10.1001/archopht.1992.01080240041025 · Cited by 486
Hypertension, cardiovascular disease, and age-related macular degeneration
Hyman, L. (2000) · Archives of Ophthalmology · doi:10.1001/archopht.118.3.351 · Cited by 441
A prospective study of cigarette smoking and age-related macular degeneration in women
Seddon, J. M. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540140029022 · Cited by 435
Argon Laser Photocoagulation for Senile Macular Degeneration: Results of a Randomized Clinical Trial
(1982) · Archives of Ophthalmology · doi:10.1001/archopht.1982.01030030920003 · Cited by 405
FACTORS ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION
GOLDBERG, J., FLOWERDEW, G., SMITH, E., BRODY, J. A., & TSO, M. O. M. (1988) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115023 · Cited by 384
Oral Zinc in Macular Degeneration
Newsome, D. A., Swartz, M., Leone, N. C., Elston, R. C., & Miller, E. (1988) · Archives of Ophthalmology · doi:10.1001/archopht.1988.01060130202026 · Cited by 349
A Prospective Study of Cigarette Smoking and Risk of Age-Related Macular Degeneration in Men
Christen, W. G. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540140035023 · Cited by 320 · cited 1×
“of developing AMD [15], and the Nurse’s Health Study also described similar findings for women [16].”
(1993) · Archives of Ophthalmology · doi:10.1001/archopht.1993.01090090052019 · Cited by 303
Marse-Perlman, J. A., Fisher, A. I., Klein, R., Palta, M., Block, G., Millen, A. E., & Wright, J. D. (2001) · American Journal of Epidemiology · doi:10.1093/aje/153.5.424 · Cited by 286
Comparison of Age-related Macular Degeneration Treatments Trials Research, G. (2011) · doi:10.1056/nejmicm1005605 · Cited by 273
Sarks, S., Cherepanoff, S., Killingsworth, M., & Sarks, J. (2007) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.06-0443 · Cited by 244
Cardiovascular Risk Factors and the Long-term Incidence of Age-Related Macular Degeneration
Tan, J. S. L., Mitchell, P., Smith, W., & Wang, J. J. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2006.09.033 · Cited by 238
VandenLangenberg, G. M., Mares-Perlman, J. A., Klein, R., Klein, B. E. K., Brady, W. E., & Palta, M. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009625 · Cited by 234
Bakall, B., Folk, J. C., Boldt, H. C., Sohn, E. H., Stone, E. M., Russell, S. R., & Mahajan, V. B. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.02.017 · Cited by 229
(1986) · Archives of Ophthalmology · doi:10.1001/archopht.1986.01050170084028 · Cited by 227
The association of cardiovascular disease with the long-term incidence of age-related maculopathy
Klein, R., Klein, B. E. K., Tomany, S. C., & Cruickshanks, K. J. (2003) · Ophthalmology · doi:10.1016/s0161-6420(03)00599-2 · Cited by 209
Yonekawa, Y., Andreoli, C., Miller, J. B., Loewenstein, J. I., Sobrin, L., Eliott, D., Vavvas, D. G., Miller, J. W., & Kim, I. K. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.03.030 · Cited by 166
Self-citationVitamin E supplementation and macular degeneration: randomised controlled trial
Taylor, H. R., Tikellis, G., Robman, L. D., McCarty, C. A., & McNeil, J. J. (2002) · BMJ · doi:10.1136/bmj.325.7354.11 · Cited by 165
Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab
Cho, H., Shah, C. P., Weber, M., & Heier, J. S. (2013) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2013-303344 · Cited by 161
Mata, N. L., Lichter, J. B., Vogel, R., Han, Y., Bui, T. V., & Singerman, L. J. (2013) · Retina · doi:10.1097/iae.0b013e318265801d · Cited by 157 · cited 1×
“photoreceptors [48,49], neuroprotection [1,50–53], and stem cell transplantation [54,55].”
Cardiovascular Disease and Hypertension Are Strong Risk Factors for Choroidal Neovascularization
Hogg, R. E., Woodside, J. V., Gilchrist, S. E. C. M., Graydon, R., Fletcher, A. E., Chan, W., Knox, A., Cartmill, B., & Chakravarthy, U. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2007.07.031 · Cited by 148
Klein, R., Deng, Y., Klein, B. E. K., Hyman, L., Seddon, J., Frank, R. N., Wallace, R. B., Hendrix, S. L., Kuppermann, B. D., Langer, R. D., et al. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.11.058 · Cited by 142
Cited by
Dugel, P. U., Koh, A., Ogura, Y., Jaffe, G. J., Schmidt-Erfurth, U., Brown, D. M., Gomes, A. V., Warburton, J., Weichselberger, A., & Holz, F. G. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.04.017 · Cited by 931
Recent developments in age-related macular degeneration: a review
Al-Zamil, W., & Yassin, S. (2017) · Clinical Interventions in Aging · doi:10.2147/cia.s143508 · Cited by 406
The Role of Inflammation in Age-Related Macular Degeneration
Tan, W., Zou, J., Yoshida, S., Jiang, B., & Zhou, Y. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.49890 · Cited by 311
Clinical applications of fundus autofluorescence in retinal disease
Yung, M., Klufas, M. A., & Sarraf, D. (2016) · International Journal of Retina and Vitreous · doi:10.1186/s40942-016-0035-x · Cited by 236
“FAF can be an important tool to monitor non-neovascular AMD—especially GA, the second most important etiology of severe vision loss in AMD after choroidal neovascularization [83].”
BackgroundWinkler, T. W., Grassmann, F., Brandl, C., Kiel, C., Günther, F., Strunz, T., Weidner, L., Zimmermann, M. E., Korb, C. A., Poplawski, A., et al. (2020) · BMC Medical Genomics · doi:10.1186/s12920-020-00760-7 · Cited by 138
Metadata
- Authors
- Yonekawa, Y., Miller, J., & Kim, I.
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2015-02-12
- Volume
- 4
- Issue
- 2
- Pages
- 343-359
- ISSN
- 2077-0383 (ISSN-L)
- OpenAlex
- W2026712831
- Cited by
- 147
- References
- 37
- FWCI
- 11.87
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.